Related Experiment Videos
[40-year-old man with primary antiphospholipid syndrome]
A Rodríguez Jornet1, F J Andreu, C Tolosa
1Unidad de Nefrología, Corporación Parc Taulí, 08208 Sabadell, Barcelona.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|December 25, 2002
Summary
Primary antiphospholipid syndrome can cause ischemic strokes and kidney damage. Long-term warfarin treatment is crucial for managing this condition and preventing severe hypertension.
Area of Science:
- Nephrology
- Neurology
- Rheumatology
Background:
- Primary antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent thrombotic events.
- Renal involvement in APS can manifest as microangiopathy and infarction, distinct from lupus-associated APS.
- Understanding these distinctions is vital for accurate diagnosis and management.
Observation:
- A 40-year-old male with primary APS presented with ischemic cerebral infarctions.
- The patient also developed renal microangiopathy with infarction.
- Literature review highlighted differences in renal manifestations between primary APS and APS secondary to systemic lupus erythematosus.
Findings:
- The patient's eight-year clinical evolution demonstrated the efficacy of warfarin therapy.
- Warfarin management was associated with preventing further thrombotic events and managing secondary arterial hypertension.
- Renal microangiopathy with infarction was a significant complication in this primary APS case.
Implications:
- This case underscores the importance of long-term anticoagulation with warfarin in primary APS.
- Early recognition and management of renal involvement in primary APS are critical.
- Further research into the pathophysiology of severe secondary arterial hypertension in APS is warranted.